Compare Aurora Cannabis Inc (ACB) vs Oklo Inc (OKLO) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

OKLO trades at $51.84, down 0.99% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $105.66 million for 2025 and negative cash flow from operations. Recent positive developments include DOE safety approval for its Groves Isotope Test Reactor and strategic acquisitions to accelerate reactor development.

Analyst consensus remains strongly bullish with a $96 price target, but execution risks and sustained losses pose challenges. The stock's outlook hinges on successful reactor deployment and achieving profitability amid high cash burn. Investors should weigh the high growth potential against substantial operational and regulatory hurdles.